# ADRX (ADARx Pharmaceuticals, Inc.) - SEC EDGAR Financial Statements

> ADARx Pharmaceuticals, Inc. reported $929.1M in total assets through September 30, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/ADRX
- Markdown: https://convexityos.com/fundamentals/ADRX.md
- SEC CIK: 0001802369
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:26 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001802369&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Sep 30, 2026 |
| Operating Income | FY 2026 | -- | Operating profit |
| Net Income | FY 2026 | -- | GAAP bottom line |
| Diluted EPS | FY 2026 | -- | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $901.0M | Total debt: $6.46M |

## Income Statement

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $2.22M | -- | -- | $1.55M | -- | -- |
| Research & Development | $26.71M | -- | -- | $19.42M | -- | -- |
| Selling, General & Admin | $7.68M | -- | -- | $5.15M | -- | -- |
| Total Operating Expenses | $34.39M | -- | -- | $24.56M | -- | -- |
| **Operating Income** | -$32.18M | -- | -- | -$23.01M | -- | -- |
| **EBITDA** | -$31.88M | -- | -- | -$22.71M | -- | -- |
| Interest Income | $3.48M | -- | -- | $4.62M | -- | -- |
| **Net Income** | -$28.12M | -$25.76M | -$22.67M | -$17.88M | -$18.09M | -$15.55M |
| Basic EPS | -$1.74 | -- | -- | -$1.85 | -- | -- |
| **Diluted EPS** | -$1.74 | -- | -- | -$1.85 | -- | -- |
| Basic Shares Outstanding | 16.1M | -- | -- | 9.7M | -- | -- |
| Diluted Shares Outstanding | 16.1M | -- | -- | 9.7M | -- | -- |

## Balance Sheet

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Dec 2025 |
| --- | --- | --- |
| Cash & Cash Equivalents | $570.6M | $66.52M |
| Short-Term Investments | $330.4M | $413.5M |
| **Cash & Short-Term Investments** | $901.0M | $480.0M |
| **Total Current Assets** | $918.5M | $493.4M |
| Property, Plant & Equipment, Net | $4.40M | $4.73M |
| Other Non-Current Assets | $100K | $2.21M |
| **Total Non-Current Assets** | $10.55M | $14.28M |
| **Total Assets** | $929.1M | $507.7M |
| Accounts Payable | $9.35M | $5.84M |
| Deferred Revenue (Current) | $20.92M | $16.56M |
| **Total Current Liabilities** | $43.57M | $30.48M |
| **Total Non-Current Liabilities** | $311.1M | $321.8M |
| **Total Liabilities** | $354.7M | $352.3M |
| **Total Debt (incl. Leases)** | $6.46M | $7.74M |
| Common Stock | $11K | $0 |
| Retained Earnings | -$297.2M | -$220.7M |
| Accumulated Other Comp. Income | -$2.15M | $1.96M |
| **Total Stockholders' Equity** | $574.4M | -$202.3M |
| Total Equity | $574.4M | -$202.3M |

## Cash Flow Statement

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$28.12M | -$25.76M | -$22.67M | -$17.88M | -$18.09M | -$15.55M |
| Depreciation & Amortization | $300K | -- | -- | $300K | -- | -- |
| Stock-Based Compensation | $1.9K | -- | -- | $1.4K | -- | -- |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Current Ratio | 21.08x | -- | -- | -- | -- | -- |
| Quick Ratio | 20.68x | -- | -- | -- | -- | -- |
| Debt to Equity | 0.01x | -- | -- | -- | -- | -- |
| **Revenue Growth (YoY)** | +42.6% | -- | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
